The Effect of H. Pylori Infection on Iron Metabolism
The purpose of this study is to determine if Helicobacter pylori (H. pylori) gastritis results in abnormal iron metabolism in patients with iron deficiency anemia (IDA), and to determine if this is due to strain variations in the H. pylori organism.
Iron Deficiency Anemia
Helicobacter Pylori Infection
Drug: H. pylori treatment
|Study Design:||Allocation: Non-Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||The Effect of H. Pylori Infection on Iron Metabolism|
- Difference in iron absorption (Cmax) for H. pylori infected and uninfected IDA patients.
- Change following H. pylori treatment in the iron absorption (Cmax) for H. pylori infected IDA patients.
- Difference in the presence of genes related to iron metabolism for H. pylori-infected IDA patients vs. non-anemic controls.
- Difference in gastritis pattern between H. pylori-infected IDA patients and non-anemic controls.
- Difference in gastritis severity between H. pylori-infected IDA patients and non-anemic controls.
- Difference in gastric iron concentration.
- Change in Hct and ferritin values following treatment.
|Study Start Date:||November 2002|
|Estimated Study Completion Date:||September 2007|
There is suggestive evidence that H. pylori gastritis (without peptic ulcer disease) is a cause of IDA. There have been individual case reports and case series describing patients with refractory IDA that resolved following successful H. pylori treatment. The effect of H. pylori on iron metabolism will be studied through specific aims: 1. To assess whether H. pylori results in abnormal oral iron absorption 2. To assess if differences in H. pylori strains are associated with iron deficiency due to: a. genetic differences in H. pylori strains or b. differences in the pattern of gastritis which could be due to host, bacterial or environmental factors 3. To assess if H. pylori infection results in storage of iron in the gastric mucosa and an elevated gastric iron concentration. The study will consist of three aspects: 1. Determining whether oral iron absorption is abnormal for H. pylori-positive IDA patients, and comparison of oral iron absorption for H. pylori positive and negative IDA patients. This will also include an experimental component in which oral iron absorption will be repeated after H. pylori treatment for H. pylori-infected IDA subjects (and after an equivalent time period for H. pylori negative controls to exclude changes in iron absorption that occur over time). 2. Comparison of H. pylori strain characteristics for IDA patients and non-anemic H. pylori-infected controls. Characterization of H. pylori strains will include: genetic analysis using a whole genome microarray technique that assesses the presence or absence of H. pylori genes, evaluation of expression of genes related to iron metabolism, and comparison of pattern of gastritis (pan gastritis vs. antrum-predominant). 3. Determination of whether H. pylori stores a significant quantity of iron in the gastric mucosa in vivo. This will be assessed by measuring the iron concentration in mucosal biopsy specimens and comparing results for H. pylori-infected IDA patients to H. pylori-uninfected IDA controls.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00202488
|United States, Washington|
|VA Puget Sound Health Care System|
|Seattle, Washington, United States, 98108|
|Principal Investigator:||David Kearney, MD||University of Washington|